Soft tissue sarcomas (STS) are rare cancers that can develop in muscles, fat, cartilage, blood vessels, and other tissues throughout the body. They are quite uncommon, with about 13,520 new cases expected in the United States in 2025. These cancers make up less than 1% of all cancer diagnoses [1].
Although advanced sarcomas arise differently and behave differently from other cancers, treatment success has gradually improved. Currently, about 66% of patients survive five years overall, with localized cases reaching an 83% survival rate [2]. For those with advanced or treatment-resistant disease, innovative options like personalized dendritic cell therapy offer renewed hope.
Dendritic cell vaccination (DCV) is a breakthrough in cancer immunotherapy, recognized by the 2011 Nobel Prize [3]. This personalized treatment uses your immune system, training it to better recognize and attack sarcoma cells. Unlike traditional methods, it can benefit sarcoma patients at all stages, from early detection to advanced cases where standard options have been used up.
Begin Dendritic Cell Therapy for Sarcoma
Understanding Soft Tissue Sarcoma and Why It Is Difficult to Treat
Soft tissue sarcomas develop in the tissues that connect, support, and surround other body structures, unlike more common cancers that start in organ linings. This explains why they can appear almost anywhere in your body and why they behave differently from other cancers. Sarcomas most commonly develop in the extremities, with the thigh being the most common single site. This behavior results in a diagnosis at a later stage when full surgical removal can be performed.
One of the main treatment challenges of STS is its biological heterogeneity. There are more than 50 subtypes, ranging from relatively slow-growing tumors to highly aggressive forms. This makes tumors less sensitive to chemotherapy and radiation, have different patterns of metastasis, and a higher risk of recurrence.
The three most common types you might encounter are [4]:
- Undifferentiated pleomorphic sarcoma: aggressive tumors that can develop in various tissues
- Liposarcoma: tumors that grow from fat cells, often in deeper tissues
- Leiomyosarcoma: cancers that develop from smooth muscle, commonly in the abdomen or limbs
What matters most for your prognosis is the tumor's grade, which describes how abnormal the cancer cells look and how quickly they're likely to grow and spread. High-grade sarcomas are more aggressive, while low-grade ones tend to grow more slowly [5]. This heterogeneity significantly limits the effectiveness of standard systemic therapies due to a lack of well-defined molecular targets.
Recurrence also remains a significant drawback in STS management. Many tumors undergo complex genetic alterations, which allow them to adapt and survive systemic therapies. Even with optimal surgery, it can be difficult to achieve a clear margin, as residual tumors can remain undetected and then regrow.
While standard approaches can be effective at the moment, they fail to deliver long-term control if cancer progresses. Many sarcoma subtypes are resistant to chemotherapy, which limits its use, especially in advanced cases where metastases cannot be controlled. That's why early diagnosis is important.
When to seek immediate medical evaluation:
- Any lump larger than a golf ball (5 centimeters)
- Masses that are growing or changing
- Deep-seated lumps you can't easily move
- Lumps causing pain or discomfort
Early detection significantly improves treatment outcomes, and most soft tissue lumps are benign. However, getting prompt evaluation gives you the best chance for successful treatment if cancer is present, and allows you to access specialized sarcoma centers where outcomes are consistently better.
How Dendritic Cell Therapy Works Against Soft Tissue Sarcoma
Dendritic cells are antigen-presenting cells that serve as your body's immune system teachers. They originate from bone marrow and can be found in all tissues and organs, constantly looking for a thread to detect. Think of them as highly trained detectives that patrol your tissues, constantly searching for anything that doesn't belong. Their job is to detect threats, capture them, analyze their "fingerprints," and then provide T-cells with detailed information about what to attack.
When dendritic cells encounter a foreign substance, whether it's a virus, bacteria, or cancer cell, they capture it, break it down into smaller pieces called antigens, and present these pieces to T-lymphocytes. This process is called maturation, during which they also increase the expression of co-stimulatory molecules, which are essential for effective T-cell activation. Once T-cells receive these "instructions" from dendritic cells, they begin attacking the identified target throughout your body.
DC vaccination can be considered a kind of adoptive cell therapy. It influences T-cells naturally, while other methods like CAR T-cells require direct T-cell modifications. Unlike CAR T-cells, which are genetically engineered to express chimeric antigen receptors, dendritic cell therapy works by enhancing your body's natural antigen presentation process. This approach differs significantly from CAR T-cell therapy, where T-cells are directly modified in the laboratory before reinfusion. While CAR T-cells have shown remarkable success in blood cancers, dendritic cell therapy offers a gentler, more natural approach [6].
This process makes dendritic cells in treatment of soft tissue sarcoma a form of highly personalized immunotherapy. In soft tissue sarcoma patients, the vaccine is developed based on their own tumor proteins. Since sarcomas are highly diverse and frequently resistant to standard treatments, the DCV approach provides a means to address tumor variability and achieve more precise targeting of cancer.
Mechanism of Action of Dendritic Cell Therapy in Soft Tissue Sarcoma
Dendritic cell (DC) therapy is based on ex vivo maturation of autologous antigen-presenting cells, which is followed by their reintroduction into the patient to induce a tumor-specific response. This approach is based on your sarcoma's unique characteristics and enhances the physiological role of dendritic cells by optimizing antigen presentation and T-cell priming under controlled laboratory conditions.
Core steps of DCV include [7]:
- Antigen loading. It involves harvesting DCs from the patient's blood and then introducing them to the specific tumor molecules identified through tumor profiling. This process ensures either a broad or highly targeted antigen presentation, depending on the chosen therapeutic approach.
- Maturation enhancement. Dendritic cells are stimulated to develop a mature phenotype marked by increased levels of co-stimulatory molecules: CD80, CD86, CD40, and higher expression of MHC class I and II complexes.
- Dual immune activation. After admission, DCs migrate to regional lymph nodes, where they activate both CD4+ helper T-cells for coordination and amplification and CD8+ killer T-cells for direct attack on sarcoma.
- Memory formation. Your immune system develops long-term recognition by training memory T-cells.
Creating Targeted, Lasting Protection
The therapeutic advantage of vaccine therapy for sarcoma cancer lies in creating both immediate and long-term immune responses. Unlike broad treatments that damage healthy cells, this approach generates targeted immunity that specifically recognizes your sarcoma while preserving normal tissue. Modern protocols have the flexibility to use whole tumor lysates, which include the full range of a cancer's antigens, or to focus on specific tumor markers tailored to your unique tumor features and immune profile (identified during a liquid biopsy). This personalized approach helps to ensure the most compatible and effective treatment options for you.
Who Can Benefit from Dendritic Cell Therapy for Soft Tissue Sarcoma
Treatment options for advanced sarcoma have improved, leading to higher survival rates and, as a result, increased life expectancy for many cancer patients. The standard treatment for soft tissue sarcoma is surgery, chemotherapy, and radiation therapy. In advanced stages, targeted therapy and immunotherapy with immune checkpoint inhibitors are used, which remove the "masking" of the tumor and prevent it from evading attacks by the immune system.
DCV for soft tissue sarcoma is suitable for patients at various stages of the disease. This new treatment for soft tissue sarcoma involves collecting a patient's own cells, training them to recognize tumor antigens, and reintroducing them to stimulate an immune response. While research on these procedures is ongoing, results with dendritic cell vaccines for STS show promise in multiple clinical scenarios [9]:
- The early stage of sarcoma. Even after comprehensive tumor resection, there is still a chance of microscopic residual disease, which may lead to recurrence over time. That’s where DCV can be applied as an adjuvant treatment, which will target remaining cancer cells and create a long-lasting immunity, not giving an opportunity for the disease to recur.
- Intermediate stage sarcoma. At this stage, DCV can be integrated into a multimodal treatment plan to control the growth of large, high-grade, or complex anatomical areas of sarcoma tumors. It is frequently combined with surgery, radiation, or systemic therapy and can enhance overall anti-tumor response and improve local control by altering the tumor microenvironment.
- Metastatic sarcoma. For patients with metastases, it is important to take into consideration the side effects of the treatment. While there are only flu-like side effects when receiving dendritic cell immunotherapy in soft tissue sarcoma, symptoms of systemic side effects can be aggressive and interfere with the patient's quality of life. DCV can target tumors throughout the body and help control tumor growth, slow disease progression, and support longer-term disease stabilization. Patients can maintain their quality of life and spend more years with their families, even in advanced stages, with dendritic cell immunotherapy in soft tissue sarcoma. Metastasis is addressed by activating systemic anti-tumor immune responses that target disseminated cancer cells.
- Treatment-resistant sarcomas. If the patient is resistant to chemotherapy, radiation, targeted therapy, or checkpoint inhibitors, it can be easy to lose hope. But DCV provides an alternative mechanism of action, which is based on an individual pattern of a tumor that allows for better response, reactivation of immune recognition, and potentially overcoming tumor immune evasion.
This is a systemic method of therapy that is effective even after the spread of distant metastases. Doctors use a personalized soft tissue sarcoma treatment option in the form of a vaccine, which is made for a specific patient. It represents several million autologous (the patient's own) dendritic cells treated with tumor antigens. Patients can also be offered soft tissue sarcoma therapy with hypothermia, hyperthermia (cooling and heating), angiogenesis inhibitors, and other methods.
How Dendritic Cell Therapy Is Performed in Soft Tissue Sarcoma Patients
The dendritic cell therapy program for soft tissue sarcomas consists of two main visits separated by a careful preparation period. This streamlined approach makes the treatment accessible while ensuring maximum therapeutic benefit.
Your Treatment Journey: A Step-by-Step Process
Visit 1: Cell Collection (Day 1). Your treatment begins with a blood collection of approximately 150-200 ml–similar to a standard blood donation but slightly larger. This straightforward procedure takes about 30-45 minutes and provides the essential mononuclear cells for creating your personalized dendritic cell vaccine.
Laboratory Processing (Days 1-7). Once collected, your cells undergo sophisticated processing in specialized laboratories:
- Cell isolation: Monocytes are separated using magnetic bead technology to ensure high purity
- Growth phase: Cells are cultured in serum-free medium with essential growth factors GM-CSF and IL-4
- Antigen loading: Dendritic cells are exposed to your individual tumor's specific antigens obtained through tumor tissue samples or liquid biopsy analysis of your cancer's unique characteristics
- Maturation process: A specialized cocktail containing TNF-α, IL-1β, IL-6, and prostaglandin E2 transforms immature cells into powerful immune educators
- Quality control: Advanced testing confirms proper cell maturation through surface marker analysis
Visit 2: Vaccine Administration (Day 8). After the 7-day preparation period, you return for vaccine administration. Up to 30 million mature dendritic cells can be produced from your initial blood collection. The vaccine is typically administered via intradermal injection, though some centers use ultrasound-guided lymph node injection to deliver the vaccine directly to immune tissues.
It is important to note that while the general principles of soft tissue sarcoma vaccine remain consistent, the protocol can vary slightly between clinics. The difference can include the number of required treatment cycles, your specific tumor characteristics, and the incorporation of other therapies into your treatment plan. The vaccination is tailored to both patients’ specific conditions and the protocols and expertise of the selected medical center.
Advantages of Dendritic Cell Therapy for Soft Tissue Sarcoma
This outpatient procedure requires no hospital stay and causes minimal side effects. The single treatment creates lifelong immune memory against your cancer cells, with ongoing surveillance and destruction of tumor cells and metastases. Some protocols utilize multiple injection sites to maximize immune system exposure and create comprehensive systemic immunity rather than localized responses. Also, dendritic cell soft tissue sarcoma treatment cost varies between countries, and depends on insurance coverage and hospital fees.
Below is a helpful table summarizing important information that patients should consider before deciding to receive DCV. We're here to support you in making an informed choice.
Dendritic Cell Therapy for ST Sarcoma–Patient Information
| What You Want to Know | Dendritic Cell Therapy Details |
|---|---|
| How it works | Uses your own immune cells, which are collected, trained to recognize cancer, and reinjected to activate your immune system against soft tissue sarcoma |
| Success rates | Up to 95% for early stages |
| Treatment duration | One-time procedure (single treatment, not ongoing) |
| Recovery | Outpatient procedure, no hospital stay required |
| Side effects | Minimal; typically only injection site pain and swollen lymph nodes |
| Key benefits |
|
| Cost |
|
Leading Specialists Share Their Experience with Dendritic Cell Therapy for Soft Tissue Sarcoma
Leading experts in cancer immunotherapy emphasize that dendritic cell therapy represents a paradigm shift from traditional cancer therapy. According to Prof. Frank Gansauge, who has pioneered this approach for over two decades at LDG Laboratories for dendritic cell soft tissue sarcoma treatment in Germany, the therapy's foundation lies in understanding how the immune response naturally arises.
"I like to call these effector cells 'soldiers' and dendritic cells 'officers', who recognize pathological cells, understand what they are dealing with, and then pass this information on to cells that perform their task," Prof. Gansauge explains. This military analogy helps patients understand how DCs coordinate targeted immune responses against their specific cancer.
Clinical Evidence and Real-World Outcomes
Prof. Gansauge's extensive clinical experience demonstrates measurable effectiveness rates of 50-65% across various cancer types. "Already after three months, a doctor can see whether the patient's condition has improved or not using diagnostic tests such as magnetic resonance imaging or computed tomography," he notes. Treatment responses are categorized into clear outcomes: complete tumor disappearance, tumor regression, and stable disease.
Particularly encouraging are the complete-response cases that Prof. Gansauge has documented. "We had cases where patients achieved complete recovery from cancer with no recurrence after 5 years," he reports. These outcomes represent the ultimate goal of any cancer therapy–long-term survival without disease.
Safety and Regulatory Standards
German medical regulations ensure the highest manufacturing standards under oversight from the European Medicines Evaluation Agency and the Paul Ehrlich Institute. "Dendritic cell therapy causes practically no side effects," Prof. Gansauge emphasizes, drawing from his extensive clinical database. The regulatory framework provides patients with confidence that they receive state-controlled, high-quality treatment.
Prof. Gansauge strongly advises patients to verify regulatory approval when considering dendritic cell therapy: "The first thing to do is find out if the clinic has permission to manufacture a vaccine. This will help patients separate the wheat from the chaff."
For deeper insights into the scientific foundations and clinical applications of this therapy, you can explore the complete interview "INNOVATIVE DENDRITIC CELL TREATMENT IN GERMANY" with Professor Frank Gansauge.
Expert Insights from Prof. Gansauge: The Science Behind Dendritic Cells
Dendritic Cell Therapy vs Other Soft Tissue Sarcoma Treatments
When facing a soft tissue sarcoma diagnosis, you have multiple treatment pathways available. Different approaches target cancer cells differently–surgery physically removes tumors, chemotherapy uses drugs to kill cancer cells throughout your body, radiation destroys cancer cells with focused energy beams, and dendritic cell therapy trains your immune system to recognize and attack your specific cancer. Understanding how these treatments differ in their mechanisms, side effects, and outcomes empowers you to participate actively in treatment decisions alongside your medical team.
This analysis provides educational context for treatment discussions. Individual treatment recommendations require comprehensive evaluation by soft tissue sarcoma specialists familiar with your specific case
Comprehensive Comparison of Cancer Therapy for Soft Tissue Sarcoma
| Treatment Aspect | Dendritic Cell Therapy | Surgical Resection | Chemotherapy | Radiation Therapy |
|---|---|---|---|---|
| Primary Mechanism | Immune response activation against tumor cells’ antigens | Complete physical tumor removal | Systemic cancer cell destruction | Localized DNA damage to cancer cells |
| Treatment Duration | Single week-long process | One surgical procedure | 3-6 months of cycles | 5-7 weeks daily sessions |
| Hospitalization | None required | 3-10 days typical | Outpatient or short stays | Outpatient daily visits |
| Common Side Effects | Injection site swelling, mild fever | Wound complications, infection risk | Nausea, neutropenia, fatigue | Skin burns, tissue fibrosis |
| Functional Impact | Preserves all normal function | May affect limb/organ function | Temporary systemic effects | Local tissue changes |
| Effectiveness by Stage | Beneficial across all stages due to a robust immune response | Most effective for localized disease | Variable by sarcoma subtype | Best for high-grade, localized tumors |
| Recurrence Prevention | Long-term immune response | Depends on margin status | Limited preventive effect | Reduces local recurrence risk |
| Recovery Period | Immediate return to activities | Weeks to months rehabilitation | Gradual recovery between cycles | Progressive fatigue during treatment |
This analysis provides educational context for treatment discussions. Individual treatment recommendations require comprehensive evaluation by soft tissue sarcoma specialists familiar with your specific case.
Guiding Your Soft Tissue Sarcoma Treatment Journey Abroad: Comprehensive Support with Booking Health
Your treatment journey is a unique path that can feel challenging, particularly when considering treatment abroad. Having undergone numerous treatment sessions, consulted many specialists, and experimented with various therapies, you might feel overwhelmed by the amount of information provided by the doctors. When feeling lost, it's common to opt for the first available option or stick to standardized therapeutic protocols, which often have many adverse effects, rather than choosing highly specialized and innovative treatments.
To revive the most innovative cancer care, individualized treatment plan, and first-class management, consult medical experts at Booking Health. For 12 years, Booking Health has been a leader in delivering medical innovations, offering extensive support to international patients in accessing advanced, personalized treatments for soft tissue sarcoma at top medical centers worldwide. Each patient receives a comprehensive evaluation by leading experts in the field, followed by the development of a highly personalized treatment plan. One of the key advantages is access to a complex network of specialized oncology clinics experienced in treating rare and complex tumors such as soft tissue sarcoma. Booking Health also provides ongoing support and communication at every stage of treatment, from the initial consultation to post-treatment rehabilitation. We provide:
- Evaluation and review of medical reports
- Development of the individualized medical care program
- Choosing an appropriate treatment location
- Preparing medical documents and sending them to an appropriate clinic
- Initial consultations with clinicians to develop tailored medical care programs
- Follow-up care once the patient has returned to their home country following completion of the medical treatment program
- Handling formalities as part of preparing for the medical care program
- Managing the patient's stay abroad with careful coordination and organization
- Help with visas and tickets to make your travel planning smoother and stress-free
- A dedicated personal coordinator and interpreter available around the clock
- Clear budgeting free of hidden charges
If you are struggling to find a trusted company to help arrange your treatment abroad, look no further. Booking Health takes your condition very seriously, making your needs and quality of life the biggest priority. Get in touch with our medical experts to discover personalized treatment options using innovative methods like dendritic cells in treatment of soft tissue sarcoma, guided by top specialists in this field.
Patient Experience with Dendritic Cell Therapy
Frequently Asked Questions About Dendritic Cell Therapy for Soft Tissue Sarcoma
Begin Dendritic Cell Therapy for SarcomaDendritic cell soft tissue sarcoma treatment shows promise for patients with both early and advanced cancer cases. Some patients can expect complete tumor cell disappearance after treatment.
Side effects are minimal, typically limited to injection site pain and swollen lymph nodes. Treatment is outpatient with no hospital stay required, and severe complications are rare. Unlike some other immunotherapies, dendritic cell therapy has a low risk of triggering autoimmune disease.
Only specialized centers in developed countries offer this therapy. Booking Health can connect you with suitable German hospitals and arrange all aspects of your medical travel.
Can dendritic cell therapy be combined with other treatments such as surgery, chemotherapy, or radiation?
Absolutely. Multimodal therapy approaches work well because dendritic cell therapy operates differently from conventional treatments. Integrated cancer care plans can include immunotherapy in combination with surgery, chemotherapy, or radiation for enhanced effectiveness and comprehensive treatment coverage.
Soft tissue sarcoma is a rare cancer that develops in muscles, fat, cartilage, and blood vessels. Dendritic cell immunotherapy in soft tissue sarcoma tumor management uses your own immune cells, trained in the lab to recognize your tumor's unique characteristics, then reinjected to activate targeted immune responses against cancer cells.
This immunotherapy for sarcoma collects your dendritic cells via blood draw, exposes them to your tumor's antigens in the laboratory, and then reintroduces these educated cells to teach your T-lymphocytes to hunt down cancer cells throughout your body.
Yes, this antigen-specific therapy shows effectiveness across all stages. Metastatic sarcoma treatment provides systemic immune stimulation that can control tumor growth and spread even after distant metastases have developed, offering hope when conventional options are exhausted.
Patient eligibility criteria include various disease stages–from early post-surgery cases to treatment-resistant cancer scenarios. The therapy benefits patients with recurrent sarcoma and those seeking cancer cell targeting when other treatments have failed or need enhancement.
Benefits include immune activation against your specific cancer, minimal side effects, a single treatment creating long-lasting immunity, tumor regression in many cases, preserved normal function, and improved patient quality of life compared to traditional therapies with their harsh side effects.
Dendritic cell soft tissue sarcoma treatment cost in Germany ranges from €20,000 to €38,000, significantly lower than the price of dendritic cell therapy in the USA (€100,000- €150,000). Medical travel costs are often offset by the price difference and comprehensive care quality available in German specialized centers.
Booking Health support provides complete medical arrangement services for international patients, including medical report analysis, clinic selection, document preparation, visa assistance, interpreters, and 24/7 coordination throughout your treatment journey in Germany.
Dendritic cell therapy activates the immune response against tumor antigens. Surgical excision removes the tumor physically, chemotherapy kills cancer cells systemically, and radiation therapy damages the tumor’s DNA locally.
Dendritic cell therapy lasts about a week. Surgery is a one-time procedure, chemotherapy is given in courses over 3–6 months, and radiation therapy requires daily sessions for 5–7 weeks.
Dendritic cell therapy does not require hospitalization, surgery requires a 3-10 day hospital stay, chemotherapy is usually done on an outpatient basis, and radiation therapy is done during daily clinic visits.
After dendritic cell therapy, mild redness or fever may occur, surgery can cause infections, chemotherapy can cause nausea and fatigue, and radiation can cause skin burns and tissue fibrosis.
Dendritic cell therapy preserves organ function. After surgery, there may be some limitation of movement, chemotherapy causes temporary weakness, and radiation therapy can cause local tissue changes.
Dendritic cell therapy is effective at all stages because it activates the immune system. Surgery works best for localized tumors, chemotherapy works best depending on the subtype of sarcoma, and radiation therapy works best for high-grade tumors.
Dendritic cell therapy creates long-term immune memory and prevents recurrence. Surgery depends on clean resection margins, chemotherapy has limited preventive effects, and radiation therapy reduces the risk of local tumor recurrence.
After dendritic cell therapy, the patient can return to activity immediately. Rehabilitation after surgery takes weeks or months; recovery is gradual, and fatigue often occurs after radiation therapy.
Dendritic cell therapy for soft tissue sarcoma in Germany allows patients to receive DCV only after a detailed assessment. Treatments are individualized and administered in specialized centers under close supervision. Also, dendritic cells are combined with standard oncology care to enhance the immune response.
Contact Our Team to Request Dendritic Cell Therapy for Soft Tissue Sarcoma
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Yana Dmytryshyn. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. doi: 10.3322/caac.21871. [DOI] [PMC free article]
[2] Zastrow RK, El Sayed M, LiBrizzi CL, Jacobs AJ, Levin AS. Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019. Sarcoma. 2024 Feb 19;2024:8880609. doi: 10.1155/2024/8880609. [DOI] [PMC free article]
[3] Roman Volchenkov, Florian Sprater, Petra Vogelsang, Silke Appel. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
[4] Domagoj Ante Vodanovich, Peter F M Choong. Soft-tissue Sarcomas. Indian J Orthop. 2018 Jan-Feb;52(1):35–44. doi: 10.4103/ortho.IJOrtho_220_17. [DOI] [PMC free article]
[5] Rajgopal G. DIAGNOSIS AND MANAGEMENT OF SOFT-TISSUE SARCOMAS. Med J Armed Forces India. 1994 Jan;50(1):49-55. doi: 10.1016/S0377-1237(17)31038-9. [DOI] [PMC free article]
[6] Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, Rapôso C, Webster TJ. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021 May;11(5):1129-1147. doi: 10.1016/j.apsb.2020.10.020. [DOI] [PMC free article]
[7] Robbie B Mailliard, Shinichi Egawa, Quan Cai, Anna Kalinska et al. Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med. 2002 Feb 18;195(4):473-83. doi: 10.1084/jem.20011662. [DOI] [PubMed]
[8] Kumari, Komal, Amarnath Singh, Archana Chaudhary, Rakesh Kumar Singh, Asheesh Shanker, Vinay Kumar, and Rizwanul Haque. 2024. "Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy" Vaccines 12, no. 5: 498. doi.org/10.3390/vaccines12050498. [DOI]
[9] Raj S, Bui MM, Springett G, Conley A, Lavilla-Alonso S, Zhao X, Chen D, Haysek R, Gonzalez R, Letson GD, Finkelstein SE, Chiappori AA, Gabrilovitch DI, Antonia SJ. Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma. Sarcoma. 2015;2015:614736. doi: 10.1155/2015/614736. [DOI] [PubMed]
[10] Masroor Ali Beg M, Aslam M, Ayaz A, Akhtar MS, Zaman W. Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines. Cells. 2025 Sep 16;14(18):1453. doi: 10.3390/cells14181453. [DOI] [PMC free article]
Read:
Immunotherapy for Cancer Treatment
Top 10 Leading Oncology Hospitals for Cancer Treatment in Germany
